SYRE: Spyre sold 7.475M shares at $62.00 for $435.2M net in April
Q3 2026 net loss of $96.1M vs $11.2M a year ago; April 2026 offering raised $435.2M net at $62/share.
What this filing says
Spyre Therapeutics reported a quarterly net loss of $96.1 million for the period ended September 30, 2026, against $11.2 million a year earlier. In April 2026 the company raised about $435.2 million net by selling 7,475,000 new shares, including the full over-allotment option. Shareholders should note that new shares dilute existing holders, and the filing also flags regulatory risk around FDA leadership and budget changes.
Key figures
- Quarterly net loss
- $96,121 thousand
- Prior-year quarterly net loss
- $11,183 thousand
- Shares sold in April 2026 offering
- 7,475,000 shares
- Public offering price per share
- $62.00
- Net proceeds from April 2026 offering
- $435.2 million
- Underwriting discounts and offering costs
- $28.2 million
Positive for shareholders
- The April 2026 offering brought in about $435.2 million net, which strengthens the company's cash position.
Negative for shareholders
- Net losses were far larger than a year earlier, rising to $96.1 million in the quarter.
- The April offering added 7,475,000 new shares, which dilutes existing holders.
- The filing warns that changes in FDA leadership and budget pressures could delay clinical trial timelines.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Over-allotment option:
- An arrangement that lets underwriters sell extra shares beyond the original offering, usually when demand is strong.
- Anti-dilutive:
- A term for securities that would reduce loss per share if counted, so they are excluded when the company reports a net loss.
- Breakthrough therapy designation:
- An FDA designation for drugs showing substantial improvement over existing treatments, intended to speed development, though it does not guarantee faster approval.
FAQ
How much did Spyre Therapeutics raise in its April 2026 share sale?
The company sold 7,475,000 shares at $62.00 each, resulting in net proceeds of about $435.2 million after $28.2 million of underwriting discounts and other costs.
Why did Spyre's net loss increase this quarter?
The filing reports a net loss of $96,121 thousand for the quarter, but it does not give a specific cause for the increase in the portion provided.
Historical context for SYRE
Across the 25 sessions after earlier SYRE headlines, the stock closed higher 17 times and lower 8 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SYRE | SPY |
|---|---|---|---|
| Nov 4, 2026 | Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | -0.2% | +1.7% |
| Oct 19, 2026 | Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 | +6.0% | +0.4% |
| Oct 12, 2026 | UBS initiated coverage on Spyre Therapeutics with a new price target | +0.2% | -0.1% |
| Oct 6, 2026 | Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stockand 1 other headline that session | -13.6% | +0.5% |
| Oct 5, 2026 | Spyre Therapeutics Announces Grants of Inducement Awards | -0.5% | +0.7% |
| Oct 1, 2026 | Analyst initiated coverage on Spyre Therapeutics with a new price target | +1.0% | +0.2% |
Keep researching SYRE
- SYRE financial statementsRevenue, profit, cash flow and balance sheet from Spyre Therapeutics Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- SYRE insider tradesEvery buy and sale reported by Spyre Therapeutics Inc. officers, directors and large holders.
- SYRE earnings historyPast Spyre Therapeutics Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Follow SYRE and get a push notification the moment its next story breaks.